Literature DB >> 19703565

Superoxide dismutase in amyotrophic lateral sclerosis patients homozygous for the D90A mutation.

P Andreas Jonsson1, Karin S Graffmo, Peter M Andersen, Stefan L Marklund, Thomas Brännström.   

Abstract

The most common of the amyotrophic lateral sclerosis (ALS)-associated superoxide dismutase-1 (SOD1) mutations, D90A, differs from others in its high structural stability and by the existence of both recessive and dominant inheritance. Here SOD1 in CNS and peripheral organs from five ALS patients homozygous for D90A were compared to controls. In most areas, including ventral horns, there were no significant differences in SOD1 activities and Western blotting patterns between controls and D90A cases. The SOD1 activities in areas vulnerable to mutant SOD1s, ventral horns and precentral gyrus were intermediate among CNS areas and much lower than in kidney and liver. Thus, the vulnerability of motor areas is not explained by high SOD1 content. The findings argue against the idea of expression-reducing protective factors being present near the D90A locus in recessive pedigrees. The similarity to wild-type SOD1 prompts speculations on the involvement of the latter in sporadic ALS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19703565     DOI: 10.1016/j.nbd.2009.08.006

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  8 in total

1.  Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients.

Authors:  Karin Forsberg; P Andreas Jonsson; Peter M Andersen; Daniel Bergemalm; Karin S Graffmo; Magnus Hultdin; Johan Jacobsson; Roland Rosquist; Stefan L Marklund; Thomas Brännström
Journal:  PLoS One       Date:  2010-07-14       Impact factor: 3.240

2.  Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations.

Authors:  Dale J Lange; Mona Shahbazi; Vincenzo Silani; Albert C Ludolph; Jochen H Weishaupt; Senda Ajroud-Driss; Kara G Fields; Rahul Remanan; Stanley H Appel; Claudia Morelli; Alberto Doretti; Luca Maderna; Stefano Messina; Ulrike Weiland; Stefan L Marklund; Peter M Andersen
Journal:  Ann Neurol       Date:  2017-06-09       Impact factor: 10.422

3.  The molecular pathogenesis of superoxide dismutase 1-linked ALS is promoted by low oxygen tension.

Authors:  Isil Keskin; Elin Forsgren; Manuela Lehmann; Peter M Andersen; Thomas Brännström; Dale J Lange; Matthis Synofzik; Ulrika Nordström; Per Zetterström; Stefan L Marklund; Jonathan D Gilthorpe
Journal:  Acta Neuropathol       Date:  2019-03-12       Impact factor: 17.088

4.  Peripheral administration of SOD1 aggregates does not transmit pathogenic aggregation to the CNS of SOD1 transgenic mice.

Authors:  Isil Keskin; Elaheh Ekhtiari Bidhendi; Matthew Marklund; Peter M Andersen; Thomas Brännström; Stefan L Marklund; Ulrika Nordström
Journal:  Acta Neuropathol Commun       Date:  2021-06-22       Impact factor: 7.801

5.  Autonomic etiology of heart block in amyotrophic lateral sclerosis: a case report.

Authors:  Kamal Shemisa; David Kaelber; Sahil A Parikh; Judith A Mackall
Journal:  J Med Case Rep       Date:  2014-06-24

6.  Low autophagy capacity implicated in motor system vulnerability to mutant superoxide dismutase.

Authors:  Eiichi Tokuda; Thomas Brännström; Peter M Andersen; Stefan L Marklund
Journal:  Acta Neuropathol Commun       Date:  2016-01-25       Impact factor: 7.801

7.  Mutant superoxide dismutase aggregates from human spinal cord transmit amyotrophic lateral sclerosis.

Authors:  Elaheh Ekhtiari Bidhendi; Johan Bergh; Per Zetterström; Karin Forsberg; Bente Pakkenberg; Peter M Andersen; Stefan L Marklund; Thomas Brännström
Journal:  Acta Neuropathol       Date:  2018-10-03       Impact factor: 17.088

Review 8.  Does wild-type Cu/Zn-superoxide dismutase have pathogenic roles in amyotrophic lateral sclerosis?

Authors:  Yoshiaki Furukawa; Eiichi Tokuda
Journal:  Transl Neurodegener       Date:  2020-08-19       Impact factor: 8.014

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.